Immune Response to Booster(s) Vaccination against SARS-CoV-2 in Different Cohorts

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 2275

Special Issue Editors


E-Mail Website
Guest Editor
Department of Clinical Biochemistry and Laboratory Diagnostics, Institute of Medical Sciences, University of Opole, Opole, Poland
Interests: SARS-CoV-2 immunity; adipose biology; disease markers; clinical biochemistry; immunology; cancer

E-Mail Website
Guest Editor
Department of Histology, Institute of Medical Sciences, University of Opole, Opole, Poland
Interests: immunology; SARS-CoV-2; histology; transplantology

Special Issue Information

Dear Colleagues,

We are honored to invite you to participate in this Special Issue of Vaccines, to present the significance of the booster vaccination(s) and its effectiveness in reducing reinfection, severe diseases and death.          

Because of the emergence of novel variants of concern and variants being monitored, cross-variant immunity is of high public relevance. The answers to the questions regarding correlates of IgG anti-SARS-CoV-2 titers versus reinfection, severe disease and death risk are still being investigated. The immunological response is encouraging, but future investigations are needed. Therefore, identifying immune protection correlations, including titers of antibodies, as well as neutralization titers of antibodies, and the T-cell immune response against SARS-CoV-2, could give us a clue. Serological tests constitute an integral element of SARS-CoV-2 infection prevention and control strategies. They are important for assessing the incidence of coronavirus infection and monitoring seroconversion in the population. 

This Special Issue will feature original research articles and reviews related to:

  • Early- and long-term responses to booster(s) vaccination;
  • Differences in the immune response between booster(s) vaccination;
  • Differences in the immune response in immunocompetent and immunocompromised cohorts;
  • Significance of SARS-CoV-2 serology testing for effective pandemic management and reduction of the occupational risk;
  • The correlation of anthropometric and biochemical parameters with IgG and/or IgM and/or IgA antibody titers after booster(s) vaccination;
  • Whether serum levels of fat-related adipokines are modulated and/or correlated with clinical and biochemical parameters of severe COVID-19 patients;
  • Evaluation and comparison of serological methods for COVID-19 diagnosis (ELISA, LFIA, CLIA).

We look forward to receiving your contributions.

Prof. Dr. Rafał Bułdak
Dr. Elżbieta Woźniak-Grygiel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV-2
  • immune response
  • humoral and cellular response
  • booster(s) vaccination
  • neutralization antibodies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1281 KiB  
Article
Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study
by Sebastián Mondaca, Benjamín Walbaum, Nicole Le Corre, Marcela Ferrés, Alejandro Valdés, Constanza Martínez-Valdebenito, Cinthya Ruiz-Tagle, Patricia Macanas-Pirard, Patricio Ross, Betzabé Cisternas, Patricia Pérez, Olivia Cabrera, Valentina Cerda, Ivana Ormazábal, Aldo Barrera, María E. Prado, María I. Venegas, Silvia Palma, Richard Broekhuizen, Alexis M. Kalergis, Susan M. Bueno, Manuel A. Espinoza, M. Elvira Balcells and Bruno Nerviadd Show full author list remove Hide full author list
Vaccines 2023, 11(7), 1193; https://doi.org/10.3390/vaccines11071193 - 3 Jul 2023
Cited by 2 | Viewed by 1884
Abstract
Cancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized with an [...] Read more.
Cancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized with an inactivated (CoronaVac) or homologous (BNT162b2) SARS-CoV-2 vaccine. The primary outcome was the proportion of patients with anti-SARS-CoV-2 neutralizing antibody (NAb) seropositivity at 8–12 weeks post-booster. The secondary end points included IgG antibody (TAb) seropositivity and specific T-cell responses. A total of 109 patients were included. Eighty-four (77%) had heterologous vaccine schedules (two doses of CoronaVac followed by the BNT162b2 booster) and twenty-five had (23%) homologous vaccine schedules (three doses of BNT162b2). IgG antibody positivity for the homologous and heterologous regimen were 100% and 96% (p = 0.338), whereas NAb positivity reached 100% and 92% (p = 0.13), respectively. Absolute NAb positivity and Tab levels were associated with the homologous schedule (with a beta coefficient of 0.26 with p = 0.027 and a geometric mean ratio 1.41 with p = 0.044, respectively). Both the homologous and heterologous vaccine regimens elicited a strong humoral and cellular response after the BNT162b2 booster. The homologous regimen was associated with higher NAb positivity and Tab levels after adjusting for relevant covariates. Full article
Show Figures

Figure 1

Back to TopTop